Acute liver enzyme elevations in HIV-1-infected patients

HIV Clinical Trials

Volumn 4, Issue 6, 2003, Pages 400-410

  Livry, Claire ^a   Binquet, Christine ^a   Sgro, Catherine ^a   Froidure, Marie ^b   Duong, Michel ^b   Buisson, Marielle ^b   Grappin, Michèle ^b   Quantin, Catherine ^a   Portier, Henri ^b   Chavanet, Pascal ^b   Piroth, Lionel ^b  

^a HÔPITAL DU BOCAGE   (France)

^b Medical University of Dijon   (France)

Author keywords

Acute liver enzyme elevation; Antiretroviral therapy; Hepatitis B virus; Hepatitis C virus; HIV infection

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ANAMNESIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SUPERINFECTION; VIRUS HEPATITIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; FRANCE; HEPATITIS B; HEPATITIS C; HEPATITIS, TOXIC; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 10744224800     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/2L6M-EE7G-5PGN-FJYP     Document Type: Article

References (26)

1. John M, Flexman J, French M. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS. 1998;12:2289-2293.
2. Arribas J, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS. 1998;12:1722-1724.
3. Brau N, Leaf H, Wieczorek R, Margolis D. Severe hepatitis in three AIDS patients treated with indinavir. Lancet. 1997;349:924-925.
4. Cattelan A, Erne E, Salatino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis. 1999;29:455-456.
5. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
6. Savès M, Vandertorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine cohort, France, 1996-1998. AIDS. 1999;13:F115-F121.
7. den Brinker M, Wit F, Wertheim-van Dillen P, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
8. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother. 2000;44:3451-3455.
9. Gisolf E, Dreezen C, Danner S, Weel J, Weverling G. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis. 2000;31:1234-1239.
10. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29:41-48.
11. Wit F, Weverling G, Weel J, Jurriaans S, Lange J. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
12. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS. 1998;12:1256.
13. Melvin D, Lee J, Belsey E, Arnold J, Murphy R. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS. 2000;14:463-465.
14. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:316-318.
15. Nunez M, Lana R, Mendoza J, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:426-431.
16. Monforte A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr. 2001;28:114-123.
17. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
18. Andersen P, Gill R. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
19. Finkelstein D, Schoenfeld DSM. Analysis of multiple failure time data from an AIDS clinical trial. Stat Med. 1997;16:951-961.
20. Prentice R, Williams B, Peterson A. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373-379.
21. Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:65-68.
22. Clark S, Creighton S, Portmann B, Taylor C, Wendon J, Cramp M. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol. 2002;36:295-301.
23. Batt A, Ferrari L. Manifestations of chemically induced liver damage. Clin Chem. 1995;41:1882-1887.
24. Cooper C, Parbhakar M, Angel J. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2002;34:1259-1263.
25. Puoti M, Gargiulo F, Roldan E, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis. 2000;181:2033-2036.
26. Chung R, Evans S, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002;16:1915-1923.